COVID-19, Vaccines, and Retinal Vascular Disease

A global systematic review of 173 studies found differing associations between COVID-19 infection and vaccination and retinal vascular events, with retinal artery occlusion more common after infection and retinal vein occlusion more common after vaccination.

By Nirojini Sivachandran, MD, PhD, FRCSC

EYP-1901 Approaches a Pivotal Fall

At Retina World Congress, Ashkan M. Abbey, MD, FASRS, FAAO, reviewed the Duravyu clinical development program. Top-line data from the phase 3 LUGANO and LUCIA trials in wet AMD are expected later this year.

By Ashkan M. Abbey, MD

Avoid Aches and Pains in Retina Practice

Simple adjustments to posture, equipment positioning, and workflow can help retina specialists prevent chronic pain.

By Sunir Garg, MD, FACS, FASRS

Managing an Aggressive Case of Placoid Chorioretinopathy

At Retina World Congress, Arthi Venkat, MD, MS, explained how to differentiate ampiginous chorioretinitis from infectious retinitis in a patient with rapid vision loss.

By Arthi Venkat, MD, MS

FDA Updates: Retina Trials and Regulatory Pathways

William M. Boyd, MD, director of the FDA’s Division of Ophthalmology, discussed the agency’s evolving approaches to clinical evidence, trial design, and expedited regulatory pathways at the 2026 Retina World Congress meeting.

By Matthew Solan, senior writer

What RVO May Reveal About Systemic Health

TriNetX data presented at Retina World Congress linked BRVO and CRVO with increased risks of stroke, myocardial infarction, and carotid disease.

By Katherine E. Talcott, MD, FASRS

Recognizing MacTel Masquerades

Imaging features such as retinal thinning and ellipsoid zone loss can help differentiate MacTel from AMD and related retinal diseases.

By Jay Chhablani, MD

Can Gene Therapy Deliver Durability?

At Retina World Congress, David A. Eichenbaum, MD, examined whether late-stage intravitreal gene therapies can reduce injection burden in nAMD.

By Jim Gallagher, senior managing editor

Diagnosing and Treating Ocular Lymphoma

At the 2026 Retina World Congress meeting, Kapil Mishra, MD, explained how new diagnostic tools and treatment agents are refining management of PVRL.

By Jim Gallagher, senior managing editor

Can Home OCT Change nAMD Monitoring?

Courtney Crawford, MD, highlighted clinical data and the Protocol AO trial evaluating home OCT’s impact on monitoring and treatment decisions in AMD.

By Matthew Solan, senior writer

A Critical Eye on GLP-1 Receptor Agonists  

Emerging evidence suggests some retinal safety signals may be real, while others remain uncertain.  

By Matthew Solan, senior writer

Early PPV With ILM Peeling Shows Durable Outcomes in Selected DME Patients  

Surgery may offer an option for patients unlikely to adhere to frequent anti-VEGF treatment schedules. 

By Matthew Solan, senior writer

Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

Patricio G. Schlottmann, MD, discussed investigational imaging systems that may improve detection of peripheral diabetic retinal disease.

By Patricio G. Schlottmann, MD

TEASE Program Builds Case for Gildeuretinol in Stargardt

The TEASE clinical program has shown reductions in atrophic lesion growth. A phase 3 trial, NORTHSTAR, is currently enrolling.

By Philip Ferrone, MD

Phase 3 Ixo-Vec Program Advances

The ARTEMIS and AQUARIUS studies will evaluate the intravitreal gene therapy for neovascular AMD, after earlier trials demonstrated durable treatment effects.

By Jim Gallagher, senior managing editor

The Developing Science of Gene Therapy

Current and future applications of retinal gene therapy may reshape treatment for noninherited retinal diseases.  

By Matthew Solan, senior writer

Peptide eye drop could offer a noninvasive alternative to injections for nAMD treatment 

Phase 1 data showed that investigational CG-P5 eye drop therapy reduced central retinal thickness. 

By Matthew Solan, senior writer

Suprachoroidal Therapy Shows Promise in Postoperative Macular Edema  

Posterior steroid delivery may help resolve persistent subretinal and intraretinal fluid after complex retinal detachment surgery. 

By Matthew Solan, senior writer